ConvaTec Group Plc (LON:CTEC – Get Rating) has been given a consensus recommendation of “Hold” by the eight brokerages that are covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is GBX 249.17 ($3.24).
CTEC has been the topic of several recent research reports. Berenberg Bank reaffirmed a “buy” rating and set a GBX 250 ($3.25) price objective on shares of ConvaTec Group in a report on Wednesday, April 13th. Barclays reduced their target price on ConvaTec Group from GBX 295 ($3.84) to GBX 290 ($3.77) and set an “overweight” rating on the stock in a research note on Tuesday, March 8th. Royal Bank of Canada restated an “underperform” rating and set a GBX 195 ($2.54) price target on shares of ConvaTec Group in a research note on Thursday, March 24th. Finally, JPMorgan Chase & Co. restated an “overweight” rating on shares of ConvaTec Group in a research note on Tuesday, January 4th.
In other news, insider Kimberly Lody purchased 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 22nd. The stock was purchased at an average cost of GBX 204 ($2.65) per share, for a total transaction of £20,400 ($26,541.76).
The firm also recently disclosed a dividend, which will be paid on Thursday, May 19th. Stockholders of record on Thursday, March 31st will be given a GBX 3.16 ($0.04) dividend. The ex-dividend date of this dividend is Thursday, March 31st. This is a boost from ConvaTec Group’s previous dividend of $1.23. This represents a dividend yield of 1.81%. ConvaTec Group’s payout ratio is 1.24%.
ConvaTec Group Company Profile (Get Rating)
ConvaTec Group Plc develops, manufactures, and markets medical products and technologies worldwide. It offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, immobility, and venous disease, as well as from traumatic injury, burns, invasive surgery, and other causes.
- Schwab Stock Can Be Caught Down Here
- Snap Up Some Snap-On On Post-Earnings Weakness
- Time to Buy any Dip in Prologis Stock
- 3 Resilient Stocks to Buy for Retirement
- MarketBeat: Week in Review 4/18 – 4/22
Receive News & Ratings for ConvaTec Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConvaTec Group and related companies with MarketBeat.com's FREE daily email newsletter.